Roche Holding AG - Stock Price History | RHHBY

Historical daily share price chart and data for Roche Holding AG since adjusted for splits and dividends. The latest closing stock price for Roche Holding AG as of December 31, 1969 is 0.00.
  • The all-time high Roche Holding AG stock closing price was 0.00 on December 31, 1969.
  • The Roche Holding AG 52-week high stock price is 0.00, which is NAN% above the current share price.
  • The Roche Holding AG 52-week low stock price is 0.00, which is NAN% below the current share price.
  • The average Roche Holding AG stock price for the last 52 weeks is NaN.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Roche Holding AG Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $0.000B $65.370B
Basel, Switzerland-based Roche Holding Ltd. is a leading health care company focused on developing and commercializing innovative diagnostic and therapeutic products and services, which enable early detection and prevention of diseases as well as their treatment and monitoring. The company conducts its operations through two segments ' Pharmaceuticals and Diagnostics.Pharmaceuticals: Key focus areas in this segment include Oncology, Virology, Inflammation, Metabolism and Neuroscience. Diagnostics: The Diagnostics Division operates in four segments ' Roche Professional Diagnostics, Roche Diabetes Care, Roche Molecular Diagnostics, and Roche Tissue Diagnostics. In September 2014, Roche acquired InterMune for $8.3 billion and added Esbriet to its portfolio. During the first quarter of 2018, Roche acquired Flatiron Health and Ignyta, Inc.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $711.911B 73.74
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $374.385B 15.19
AbbVie (ABBV) United States $303.471B 15.98
Merck (MRK) United States $252.609B 16.78
Novartis AG (NVS) Switzerland $212.269B 14.11
AstraZeneca (AZN) United Kingdom $199.245B 16.95
Pfizer (PFE) United States $142.411B 9.74
Sanofi (SNY) $121.765B 11.03
Innoviva (INVA) United States $1.193B 9.93